Why the study?
Does myricetin improve post-MI outcomes in a murine model of myocardial infarction?
Does myricetin improve post-MI outcomes in a murine model of myocardial infarction?
Answers are grounded in this paper and cite their sources.
This commentary highlights a novel, pharmacologically actionable mechanism of cellular crosstalk where cardiac fibroblast ENPP1 metabolizes ATP to disrupt nonmyocyte function, which can be inhibited by myricetin to improve post-MI wound healing.
Cardiac wound healing following ischemic injury requires a well-described spatiotemporal progression of events involving multiple cell types and cell-cell interactions. While cellular crosstalk among immune cell, endothelial cell, and fibroblast populations is known to regulate these progressive phases, the role of cardiac myocytes in controlling the wound-healing program is unclear. In this issue of the JCI, Li et al. describe a mechanism of cellular crosstalk between cardiac myocytes and fibroblasts that disrupts nonmyocyte cell function and worsens wound healing outcomes following myocardial infarction (MI). This tour de force study used an arsenal of multidisciplinary approaches to identify a central role for the ectonucleotidase ENPP1 in this process. These findings have clear therapeutic implications, as the authors identified a small molecular inhibitor of ENPP1 that improved post-MI outcomes in mice. These exciting data provide impactful mechanistic information that advance the field's understanding of cardiac repair and remodeling.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an editorial in Myocardial infarction. ENPP1 inhibitor (myricetin) vs. Control was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: